摘要
目的探究布地奈德吸入联合孟鲁司特钠对小儿哮喘的临床价值。方法选取本院2017年12月-2019年3月收治的小儿哮喘患儿160例,分为A组(布地奈德吸入联合孟鲁司特钠)和B组(布地奈德)各80例。治疗1个月后开展随访观察效果。结果A组治疗总有效率100.00%,高于B组的87.50%,A组不良反应发生率1.25%,低于B组的11.25%,对比有统计学意义(P<0.05)。A组各症状消失时间短于B组,A组肺活量、PEF%、动脉氧分压等指标高于B组,二氧化碳分压低于B组,对比有统计学意义(P<0.05)。结论布地奈德吸入联合孟鲁司特钠治疗小儿哮喘具有显著效果,值得应用于临床推广。
Objective To investigate the clinical value of budesonide inhalation combined with montelukast sodium in children with asthma. Methods 160 children with asthma in our hospital from December 2017 to March 2019 were selected and divided into group A(Budesonide inhalation combined with montelukast sodium) and group B(budesonide), 80 cases each. Follow-up observation was performed 1 month after treatment. Results The total effective rate of group A was 100.00%, which was higher than 87.50% of group B. The incidence of adverse reactions in group A was 1.25%, which was lower than that in group B(11.25%). The correlation was statistically significant(P < 0.05). The disappearance time of each symptom in group A was shorter than that in group B. The vital capacity, PEF% and arterial oxygen pressure in group A were higher than those in group B. The partial pressure of carbon dioxide was lower than that in group B(P < 0.05). Conclusion Budesonide inhalation combined with montelukast sodium has significant effect in the treatment of asthma in children, and it is worthy of clinical application.
作者
王颖
WANG Ying(Pediatrics Department,Jilin Provincial People's Hospital,Changchun Jilin 130021,China)
出处
《中国卫生标准管理》
2019年第17期46-48,共3页
China Health Standard Management
关键词
布地奈德
孟鲁司特钠
小儿哮喘
肺活量
呼吸峰值流速
动脉氧分压t
Budesonide
Montelukast sodium
pediatric asthma
vital capacity
peak respiratory rate
arterial oxygen partial pressure
